These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16814850)

  • 1. Descriptions in the peer-reviewed literature of the results of phase 2 chemotherapy trials involving gynecologic malignancies: a call for greater objectivity.
    Markman M
    Gynecol Oncol; 2006 Sep; 102(3):419-20. PubMed ID: 16814850
    [No Abstract]   [Full Text] [Related]  

  • 2. "Clinical benefit rate" in phase 2 gynecologic cancer trials: implying more than the data support?
    Markman M
    Gynecol Oncol; 2010 May; 117(2):348-9. PubMed ID: 20167354
    [No Abstract]   [Full Text] [Related]  

  • 3. Effectiveness of treatments for metastatic uveal melanoma.
    Augsburger JJ; Corrêa ZM; Shaikh AH
    Am J Ophthalmol; 2009 Jul; 148(1):119-27. PubMed ID: 19375060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination chemotherapy in clinical practice: recent applications to gynecologic cancers.
    Wade ME; Williams HM
    Conn Med; 1967 Jun; 30(6):426-9. PubMed ID: 6046075
    [No Abstract]   [Full Text] [Related]  

  • 5. [Antiblastic chemotherapy in gynecologic oncology].
    Vaglio N
    Arch Ostet Ginecol; 1969; 74(2):93-132. PubMed ID: 5406259
    [No Abstract]   [Full Text] [Related]  

  • 6. [Molecular targeting therapy for gynecologic cancer].
    Hatae M; Nakamura T; Onishi Y; Yamamoto F
    Gan To Kagaku Ryoho; 2008 Feb; 35(2):233-237. PubMed ID: 18372513
    [No Abstract]   [Full Text] [Related]  

  • 7. [Current and prospective role of antiblastic chemotherapy in gynecologic oncology].
    Macchioni B; Trompeo P
    Minerva Ginecol; 1968 Feb; 20(3):272-81. PubMed ID: 4190616
    [No Abstract]   [Full Text] [Related]  

  • 8. The dangers of "cross-trial" and "cross-retrospective experience" comparisons: examples employing data in the peer-reviewed ovarian cancer literature.
    Markman M
    Cancer; 2007 May; 109(10):1929-32. PubMed ID: 17385206
    [No Abstract]   [Full Text] [Related]  

  • 9. Taxanes in the management of gynecologic malignancies.
    Markman M
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):219-26. PubMed ID: 18279063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presentations of phase 2 clinical trial abstracts at a national oncology meeting: potential implications for subsequent publication in the peer-reviewed literature.
    Markman M
    Oncology; 2006; 71(1-2):146-7. PubMed ID: 17347590
    [No Abstract]   [Full Text] [Related]  

  • 11. Techniques of chemotherapy of gynecologic cancer.
    Opipari ML
    J Am Osteopath Assoc; 1971 Aug; 70(12):1334-9. PubMed ID: 5209206
    [No Abstract]   [Full Text] [Related]  

  • 12. Examining heterogeneity in phase II trial designs may improve success in phase III.
    Tuma RS
    J Natl Cancer Inst; 2008 Feb; 100(3):164-6. PubMed ID: 18230788
    [No Abstract]   [Full Text] [Related]  

  • 13. [Chemotherapy in the gynecologic oncology].
    Minerva Med; 1971 Apr; 62(28):1474-5. PubMed ID: 5567640
    [No Abstract]   [Full Text] [Related]  

  • 14. [Neoadjuvant chemotherapy in advanced gynecologic cancer].
    Hirabayashi K
    Nihon Sanka Fujinka Gakkai Zasshi; 1995 Aug; 47(8):797-802. PubMed ID: 7594888
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical experience with the use of Tantum Rosa in cancer patients].
    Chulkova OV; Demidova LV; Udovichenko VI
    Vopr Onkol; 1997; 43(3):339-40. PubMed ID: 9245096
    [No Abstract]   [Full Text] [Related]  

  • 16. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
    Suman VJ; Dueck A; Sargent DJ
    Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
    [No Abstract]   [Full Text] [Related]  

  • 18. How to write a systematic review.
    Wright RW; Brand RA; Dunn W; Spindler KP
    Clin Orthop Relat Res; 2007 Feb; 455():23-9. PubMed ID: 17279036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Gynecologic Tumor Chemotherapy for Rare Tumors in Gynecologic Malignancies].
    Fujiwara K
    Gan To Kagaku Ryoho; 2018 Feb; 45(2):232-233. PubMed ID: 29483411
    [No Abstract]   [Full Text] [Related]  

  • 20. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
    El-Maraghi RH; Eisenhauer EA
    J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.